Share Price and Basic Stock Data
Last Updated: November 4, 2025, 12:01 am
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
GKB Ophthalmics Ltd operates in the lenses and optical care industry, with its stock price standing at ₹65.5 and a market capitalization of ₹33.0 Cr. The company has experienced fluctuating revenue trends over the past few quarters. Quarterly sales rose from ₹17.84 Cr in June 2022 to ₹22.26 Cr in June 2023, reflecting a growth trajectory. However, sales dipped to ₹20.40 Cr in September 2023 before rebounding to ₹24.04 Cr by December 2023. For the fiscal year ending March 2025, GKB reported total sales of ₹109 Cr, a significant increase compared to ₹75 Cr in March 2023. The trailing twelve months (TTM) revenue reached ₹115 Cr, indicating a positive trend. This growth is vital for the company, especially given the competitive landscape in the optical care sector, which typically sees robust demand driven by increasing awareness of eye health and vision correction solutions.
Profitability and Efficiency Metrics
GKB Ophthalmics Ltd’s profitability metrics present a challenging picture. The operating profit margin (OPM) stood at a mere 2.48% as of the latest reporting, reflecting ongoing operational struggles. The company reported a net profit of ₹-8 Cr for the current fiscal year, with an earnings per share (EPS) of ₹-13.98, a stark decline from ₹2.52 in March 2022. The interest coverage ratio (ICR) is concerning, at -0.61x, indicating that the company is not generating enough operating income to cover its interest expenses. The return on equity (ROE) is 12.7%, which is relatively strong; however, the return on capital employed (ROCE) is significantly lower at 6.00%. These figures suggest that while GKB has potential for profitability, its current operational efficiency and cost management need urgent attention to reverse the downward trend in profitability.
Balance Sheet Strength and Financial Ratios
The balance sheet of GKB Ophthalmics Ltd reveals a mixed financial health picture. The company’s total borrowings amount to ₹14 Cr against reserves of ₹47 Cr, which provides a reasonable buffer for financial stability. However, the current ratio is reported at 1.59x, indicating adequate short-term liquidity, although this is slightly below the typical sector range of 1.75-2.0. The company’s price-to-book value (P/BV) ratio is 0.58x, suggesting that the stock may be undervalued compared to its book value, which stood at ₹103.24 per share for the fiscal year ending March 2025. Additionally, the cash conversion cycle (CCC) is reported at 141 days, which is relatively high, indicating inefficiencies in managing working capital. Overall, while the company has a reasonable amount of reserves, its high CCC and moderate liquidity ratios warrant careful consideration for potential investors.
Shareholding Pattern and Investor Confidence
GKB Ophthalmics Ltd’s shareholding pattern reflects a stable yet cautious investor sentiment. Promoter holdings stood at 51.06%, indicating a controlling interest which can be a positive signal for stability. The foreign institutional investors (FIIs) hold 1.79%, while the public holds 47.17%, showcasing a diverse ownership structure. The number of shareholders has increased from 1,638 in December 2022 to 2,601 as of June 2025, suggesting growing interest in the company. However, the decline in promoter holdings from 59.09% in December 2022 to the current level may raise concerns about long-term commitment. The absence of domestic institutional investors (DIIs) further indicates a lack of institutional confidence, which could affect stock performance. This shareholder structure, while stable, poses a risk, as a higher public stake may lead to increased volatility in the stock price.
Outlook, Risks, and Final Insight
The outlook for GKB Ophthalmics Ltd hinges on its ability to address profitability challenges and improve operational efficiencies. The company’s reported sales growth is encouraging, but the persistent net losses and low operating margins present significant risks. Additionally, the high cash conversion cycle suggests potential liquidity issues that could impact future growth. Strengths include a solid promoter holding and an increase in the number of shareholders, which may provide a buffer against volatility. However, the company’s ability to navigate cost pressures and enhance profitability remains uncertain. Should GKB successfully implement strategies to improve its operational efficiency and reduce costs, it may regain investor confidence and achieve sustainable growth. Conversely, failure to address these issues could result in continued financial strain and diminished market perception.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of GKB Ophthalmics Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| GKB Ophthalmics Ltd | 34.5 Cr. | 68.5 | 112/59.0 | 103 | 0.00 % | 6.00 % | 12.7 % | 10.0 | |
| Industry Average | 0 Cr | 68.50 | 0 | 103.00 | 0.00% | 6.00% | 12.70% | 10.00 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 17.84 | 18.56 | 19.11 | 19.96 | 22.26 | 20.40 | 24.04 | 21.56 | 26.02 | 26.14 | 25.80 | 31.02 | 32.31 |
| Expenses | 15.24 | 17.02 | 19.18 | 20.35 | 20.91 | 20.69 | 24.66 | 21.56 | 24.98 | 26.20 | 26.74 | 33.88 | 31.51 |
| Operating Profit | 2.60 | 1.54 | -0.07 | -0.39 | 1.35 | -0.29 | -0.62 | 0.00 | 1.04 | -0.06 | -0.94 | -2.86 | 0.80 |
| OPM % | 14.57% | 8.30% | -0.37% | -1.95% | 6.06% | -1.42% | -2.58% | 0.00% | 4.00% | -0.23% | -3.64% | -9.22% | 2.48% |
| Other Income | 0.35 | 0.37 | -0.03 | 0.23 | 0.35 | 0.31 | 0.35 | 0.60 | 0.28 | 0.28 | 0.48 | 0.35 | 0.21 |
| Interest | 0.38 | 0.46 | 0.40 | 0.43 | 0.43 | 0.46 | 0.44 | 0.57 | 0.55 | 0.55 | 0.63 | 0.63 | 0.77 |
| Depreciation | 0.42 | 0.39 | 0.40 | 1.63 | 0.72 | 0.73 | 0.73 | 0.72 | 0.76 | 0.77 | 0.77 | 0.80 | 0.80 |
| Profit before tax | 2.15 | 1.06 | -0.90 | -2.22 | 0.55 | -1.17 | -1.44 | -0.69 | 0.01 | -1.10 | -1.86 | -3.94 | -0.56 |
| Tax % | -0.93% | -1.89% | 18.89% | -4.95% | 0.00% | 0.00% | 0.00% | 30.43% | 600.00% | 5.45% | 2.69% | 4.82% | 14.29% |
| Net Profit | 2.21 | 1.11 | -1.11 | -2.08 | 0.54 | -1.19 | -1.44 | -0.89 | 0.11 | -1.15 | -1.91 | -4.13 | -0.64 |
| EPS in Rs | 3.85 | 1.69 | -2.04 | -3.81 | 1.03 | -2.32 | -2.48 | -1.81 | -0.50 | -2.42 | -4.03 | -7.04 | -2.02 |
Last Updated: August 19, 2025, 2:40 pm
Below is a detailed analysis of the quarterly data for GKB Ophthalmics Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 32.31 Cr.. The value appears strong and on an upward trend. It has increased from 31.02 Cr. (Mar 2025) to 32.31 Cr., marking an increase of 1.29 Cr..
- For Expenses, as of Jun 2025, the value is 31.51 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 33.88 Cr. (Mar 2025) to 31.51 Cr., marking a decrease of 2.37 Cr..
- For Operating Profit, as of Jun 2025, the value is 0.80 Cr.. The value appears strong and on an upward trend. It has increased from -2.86 Cr. (Mar 2025) to 0.80 Cr., marking an increase of 3.66 Cr..
- For OPM %, as of Jun 2025, the value is 2.48%. The value appears strong and on an upward trend. It has increased from -9.22% (Mar 2025) to 2.48%, marking an increase of 11.70%.
- For Other Income, as of Jun 2025, the value is 0.21 Cr.. The value appears to be declining and may need further review. It has decreased from 0.35 Cr. (Mar 2025) to 0.21 Cr., marking a decrease of 0.14 Cr..
- For Interest, as of Jun 2025, the value is 0.77 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.63 Cr. (Mar 2025) to 0.77 Cr., marking an increase of 0.14 Cr..
- For Depreciation, as of Jun 2025, the value is 0.80 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.80 Cr..
- For Profit before tax, as of Jun 2025, the value is -0.56 Cr.. The value appears strong and on an upward trend. It has increased from -3.94 Cr. (Mar 2025) to -0.56 Cr., marking an increase of 3.38 Cr..
- For Tax %, as of Jun 2025, the value is 14.29%. The value appears to be increasing, which may not be favorable. It has increased from 4.82% (Mar 2025) to 14.29%, marking an increase of 9.47%.
- For Net Profit, as of Jun 2025, the value is -0.64 Cr.. The value appears strong and on an upward trend. It has increased from -4.13 Cr. (Mar 2025) to -0.64 Cr., marking an increase of 3.49 Cr..
- For EPS in Rs, as of Jun 2025, the value is -2.02. The value appears strong and on an upward trend. It has increased from -7.04 (Mar 2025) to -2.02, marking an increase of 5.02.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: August 23, 2025, 1:03 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 41 | 35 | 44 | 76 | 78 | 57 | 59 | 57 | 71 | 75 | 88 | 109 | 115 |
| Expenses | 34 | 34 | 44 | 75 | 77 | 56 | 56 | 55 | 66 | 72 | 88 | 112 | 118 |
| Operating Profit | 8 | 1 | -1 | 2 | 1 | 1 | 2 | 2 | 5 | 4 | 1 | -3 | -3 |
| OPM % | 18% | 2% | -2% | 2% | 2% | 2% | 4% | 4% | 7% | 5% | 1% | -3% | -3% |
| Other Income | 1 | 1 | 12 | 4 | 0 | 2 | 1 | 2 | 1 | 1 | 2 | 2 | 1 |
| Interest | 3 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 2 | 2 | 3 |
| Depreciation | 1 | 2 | 1 | 1 | 2 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 |
| Profit before tax | 5 | -2 | 8 | 3 | -1 | -2 | -2 | -1 | 2 | 0 | -3 | -7 | -7 |
| Tax % | 46% | -37% | 50% | 12% | -15% | -30% | 0% | -19% | 0% | 14% | 8% | 5% | |
| Net Profit | 4 | 0 | 4 | 3 | -1 | -1 | -2 | -1 | 2 | 0 | -3 | -7 | -8 |
| EPS in Rs | 9.61 | 0.00 | 9.51 | 6.24 | -2.34 | -2.37 | -3.65 | -1.81 | 2.52 | -0.34 | -5.57 | -13.97 | -15.51 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -100.00% | -25.00% | -133.33% | 0.00% | -100.00% | 50.00% | 300.00% | -100.00% | -133.33% |
| Change in YoY Net Profit Growth (%) | 0.00% | 75.00% | -108.33% | 133.33% | -100.00% | 150.00% | 250.00% | -400.00% | -33.33% |
GKB Ophthalmics Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 9 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 13% |
| 3 Years: | 15% |
| TTM: | 25% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -118% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 5% |
| 3 Years: | -7% |
| 1 Year: | -37% |
| Return on Equity | |
|---|---|
| 10 Years: | -3% |
| 5 Years: | -3% |
| 3 Years: | -6% |
| Last Year: | -13% |
Last Updated: September 5, 2025, 3:36 pm
Balance Sheet
Last Updated: July 25, 2025, 1:13 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 4 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves | 36 | 36 | 41 | 43 | 41 | 50 | 54 | 58 | 58 | 58 | 55 | 47 |
| Borrowings | 13 | 9 | 7 | 7 | 10 | 14 | 15 | 12 | 12 | 11 | 11 | 14 |
| Other Liabilities | 21 | 26 | 17 | 28 | 28 | 25 | 28 | 32 | 35 | 38 | 43 | 59 |
| Total Liabilities | 73 | 75 | 69 | 82 | 83 | 94 | 102 | 107 | 110 | 112 | 114 | 125 |
| Fixed Assets | 14 | 12 | 13 | 18 | 18 | 26 | 26 | 24 | 23 | 19 | 18 | 17 |
| CWIP | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 3 | 4 | 4 | 4 |
| Investments | 15 | 16 | 10 | 3 | 0 | 1 | 1 | 2 | 2 | 2 | 2 | 2 |
| Other Assets | 44 | 46 | 46 | 60 | 64 | 68 | 75 | 80 | 82 | 87 | 91 | 102 |
| Total Assets | 73 | 75 | 69 | 82 | 83 | 94 | 102 | 107 | 110 | 112 | 114 | 125 |
Below is a detailed analysis of the balance sheet data for GKB Ophthalmics Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 5.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 5.00 Cr..
- For Reserves, as of Mar 2025, the value is 47.00 Cr.. The value appears to be declining and may need further review. It has decreased from 55.00 Cr. (Mar 2024) to 47.00 Cr., marking a decrease of 8.00 Cr..
- For Borrowings, as of Mar 2025, the value is 14.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 11.00 Cr. (Mar 2024) to 14.00 Cr., marking an increase of 3.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 59.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 43.00 Cr. (Mar 2024) to 59.00 Cr., marking an increase of 16.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 125.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 114.00 Cr. (Mar 2024) to 125.00 Cr., marking an increase of 11.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 17.00 Cr.. The value appears to be declining and may need further review. It has decreased from 18.00 Cr. (Mar 2024) to 17.00 Cr., marking a decrease of 1.00 Cr..
- For CWIP, as of Mar 2025, the value is 4.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 4.00 Cr..
- For Investments, as of Mar 2025, the value is 2.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 2.00 Cr..
- For Other Assets, as of Mar 2025, the value is 102.00 Cr.. The value appears strong and on an upward trend. It has increased from 91.00 Cr. (Mar 2024) to 102.00 Cr., marking an increase of 11.00 Cr..
- For Total Assets, as of Mar 2025, the value is 125.00 Cr.. The value appears strong and on an upward trend. It has increased from 114.00 Cr. (Mar 2024) to 125.00 Cr., marking an increase of 11.00 Cr..
Notably, the Reserves (47.00 Cr.) exceed the Borrowings (14.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -5.00 | -8.00 | -8.00 | -5.00 | -9.00 | -13.00 | -13.00 | -10.00 | -7.00 | -7.00 | -10.00 | -17.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 185 | 191 | 143 | 118 | 129 | 150 | 155 | 125 | 100 | 134 | 117 | 85 |
| Inventory Days | 345 | 424 | 285 | 225 | 223 | 289 | 301 | 349 | 307 | 298 | 245 | 250 |
| Days Payable | 163 | 343 | 156 | 169 | 168 | 217 | 234 | 234 | 208 | 183 | 202 | 195 |
| Cash Conversion Cycle | 367 | 271 | 272 | 174 | 184 | 222 | 223 | 239 | 199 | 249 | 160 | 141 |
| Working Capital Days | 101 | 97 | 156 | 111 | 115 | 110 | 110 | 117 | 105 | 135 | 97 | 78 |
| ROCE % | 14% | -0% | -1% | 3% | 0% | -2% | -1% | 3% | 4% | 2% | -1% | -6% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -13.98 | -5.58 | -0.33 | 2.53 | -1.80 |
| Diluted EPS (Rs.) | -13.98 | -5.58 | -0.33 | 2.53 | -1.80 |
| Cash EPS (Rs.) | -8.28 | -0.04 | 5.78 | 8.97 | 3.52 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 103.24 | 127.37 | 133.51 | 133.75 | 131.54 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 103.24 | 127.37 | 133.51 | 133.75 | 131.54 |
| Revenue From Operations / Share (Rs.) | 216.22 | 175.09 | 149.73 | 140.73 | 112.84 |
| PBDIT / Share (Rs.) | -2.88 | 4.13 | 9.14 | 11.91 | 8.62 |
| PBIT / Share (Rs.) | -9.00 | -1.61 | 3.53 | 6.61 | 2.38 |
| PBT / Share (Rs.) | -13.71 | -5.39 | 0.21 | 3.68 | -3.08 |
| Net Profit / Share (Rs.) | -14.41 | -5.80 | 0.16 | 3.67 | -2.72 |
| NP After MI And SOA / Share (Rs.) | -13.98 | -5.58 | -0.33 | 2.53 | -1.80 |
| PBDIT Margin (%) | -1.33 | 2.36 | 6.10 | 8.46 | 7.64 |
| PBIT Margin (%) | -4.16 | -0.92 | 2.35 | 4.69 | 2.11 |
| PBT Margin (%) | -6.33 | -3.07 | 0.14 | 2.61 | -2.72 |
| Net Profit Margin (%) | -6.66 | -3.31 | 0.11 | 2.61 | -2.41 |
| NP After MI And SOA Margin (%) | -6.46 | -3.18 | -0.22 | 1.79 | -1.59 |
| Return on Networth / Equity (%) | -13.53 | -4.70 | -0.26 | 2.01 | -1.44 |
| Return on Capital Employeed (%) | -7.22 | -1.19 | 2.50 | 4.72 | 1.75 |
| Return On Assets (%) | -5.62 | -2.45 | -0.14 | 1.15 | -0.84 |
| Long Term Debt / Equity (X) | 0.05 | 0.01 | 0.01 | 0.02 | 0.01 |
| Total Debt / Equity (X) | 0.27 | 0.19 | 0.17 | 0.18 | 0.18 |
| Asset Turnover Ratio (%) | 0.90 | 0.77 | 0.34 | 0.33 | 0.26 |
| Current Ratio (X) | 1.59 | 1.89 | 2.02 | 1.91 | 1.94 |
| Quick Ratio (X) | 0.78 | 1.03 | 1.09 | 0.95 | 1.01 |
| Inventory Turnover Ratio (X) | 2.41 | 0.38 | 0.62 | 0.64 | 0.58 |
| Interest Coverage Ratio (X) | -0.61 | 1.10 | 2.75 | 4.06 | 2.14 |
| Interest Coverage Ratio (Post Tax) (X) | -2.06 | -0.53 | 1.05 | 2.25 | 0.68 |
| Enterprise Value (Cr.) | 35.49 | 42.05 | 56.08 | 46.05 | 39.02 |
| EV / Net Operating Revenue (X) | 0.32 | 0.47 | 0.74 | 0.64 | 0.68 |
| EV / EBITDA (X) | -24.45 | 20.17 | 12.17 | 7.67 | 8.98 |
| MarketCap / Net Operating Revenue (X) | 0.27 | 0.49 | 0.72 | 0.65 | 0.72 |
| Price / BV (X) | 0.58 | 0.73 | 0.87 | 0.73 | 0.65 |
| Price / Net Operating Revenue (X) | 0.27 | 0.49 | 0.72 | 0.65 | 0.72 |
| EarningsYield | -0.23 | -0.06 | 0.00 | 0.02 | -0.02 |
After reviewing the key financial ratios for GKB Ophthalmics Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -13.98. This value is below the healthy minimum of 5. It has decreased from -5.58 (Mar 24) to -13.98, marking a decrease of 8.40.
- For Diluted EPS (Rs.), as of Mar 25, the value is -13.98. This value is below the healthy minimum of 5. It has decreased from -5.58 (Mar 24) to -13.98, marking a decrease of 8.40.
- For Cash EPS (Rs.), as of Mar 25, the value is -8.28. This value is below the healthy minimum of 3. It has decreased from -0.04 (Mar 24) to -8.28, marking a decrease of 8.24.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 103.24. It has decreased from 127.37 (Mar 24) to 103.24, marking a decrease of 24.13.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 103.24. It has decreased from 127.37 (Mar 24) to 103.24, marking a decrease of 24.13.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 216.22. It has increased from 175.09 (Mar 24) to 216.22, marking an increase of 41.13.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -2.88. This value is below the healthy minimum of 2. It has decreased from 4.13 (Mar 24) to -2.88, marking a decrease of 7.01.
- For PBIT / Share (Rs.), as of Mar 25, the value is -9.00. This value is below the healthy minimum of 0. It has decreased from -1.61 (Mar 24) to -9.00, marking a decrease of 7.39.
- For PBT / Share (Rs.), as of Mar 25, the value is -13.71. This value is below the healthy minimum of 0. It has decreased from -5.39 (Mar 24) to -13.71, marking a decrease of 8.32.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -14.41. This value is below the healthy minimum of 2. It has decreased from -5.80 (Mar 24) to -14.41, marking a decrease of 8.61.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -13.98. This value is below the healthy minimum of 2. It has decreased from -5.58 (Mar 24) to -13.98, marking a decrease of 8.40.
- For PBDIT Margin (%), as of Mar 25, the value is -1.33. This value is below the healthy minimum of 10. It has decreased from 2.36 (Mar 24) to -1.33, marking a decrease of 3.69.
- For PBIT Margin (%), as of Mar 25, the value is -4.16. This value is below the healthy minimum of 10. It has decreased from -0.92 (Mar 24) to -4.16, marking a decrease of 3.24.
- For PBT Margin (%), as of Mar 25, the value is -6.33. This value is below the healthy minimum of 10. It has decreased from -3.07 (Mar 24) to -6.33, marking a decrease of 3.26.
- For Net Profit Margin (%), as of Mar 25, the value is -6.66. This value is below the healthy minimum of 5. It has decreased from -3.31 (Mar 24) to -6.66, marking a decrease of 3.35.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -6.46. This value is below the healthy minimum of 8. It has decreased from -3.18 (Mar 24) to -6.46, marking a decrease of 3.28.
- For Return on Networth / Equity (%), as of Mar 25, the value is -13.53. This value is below the healthy minimum of 15. It has decreased from -4.70 (Mar 24) to -13.53, marking a decrease of 8.83.
- For Return on Capital Employeed (%), as of Mar 25, the value is -7.22. This value is below the healthy minimum of 10. It has decreased from -1.19 (Mar 24) to -7.22, marking a decrease of 6.03.
- For Return On Assets (%), as of Mar 25, the value is -5.62. This value is below the healthy minimum of 5. It has decreased from -2.45 (Mar 24) to -5.62, marking a decrease of 3.17.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 0.2. It has increased from 0.01 (Mar 24) to 0.05, marking an increase of 0.04.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.27. This value is within the healthy range. It has increased from 0.19 (Mar 24) to 0.27, marking an increase of 0.08.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.90. It has increased from 0.77 (Mar 24) to 0.90, marking an increase of 0.13.
- For Current Ratio (X), as of Mar 25, the value is 1.59. This value is within the healthy range. It has decreased from 1.89 (Mar 24) to 1.59, marking a decrease of 0.30.
- For Quick Ratio (X), as of Mar 25, the value is 0.78. This value is below the healthy minimum of 1. It has decreased from 1.03 (Mar 24) to 0.78, marking a decrease of 0.25.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 2.41. This value is below the healthy minimum of 4. It has increased from 0.38 (Mar 24) to 2.41, marking an increase of 2.03.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -0.61. This value is below the healthy minimum of 3. It has decreased from 1.10 (Mar 24) to -0.61, marking a decrease of 1.71.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -2.06. This value is below the healthy minimum of 3. It has decreased from -0.53 (Mar 24) to -2.06, marking a decrease of 1.53.
- For Enterprise Value (Cr.), as of Mar 25, the value is 35.49. It has decreased from 42.05 (Mar 24) to 35.49, marking a decrease of 6.56.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.32. This value is below the healthy minimum of 1. It has decreased from 0.47 (Mar 24) to 0.32, marking a decrease of 0.15.
- For EV / EBITDA (X), as of Mar 25, the value is -24.45. This value is below the healthy minimum of 5. It has decreased from 20.17 (Mar 24) to -24.45, marking a decrease of 44.62.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.27. This value is below the healthy minimum of 1. It has decreased from 0.49 (Mar 24) to 0.27, marking a decrease of 0.22.
- For Price / BV (X), as of Mar 25, the value is 0.58. This value is below the healthy minimum of 1. It has decreased from 0.73 (Mar 24) to 0.58, marking a decrease of 0.15.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.27. This value is below the healthy minimum of 1. It has decreased from 0.49 (Mar 24) to 0.27, marking a decrease of 0.22.
- For EarningsYield, as of Mar 25, the value is -0.23. This value is below the healthy minimum of 5. It has decreased from -0.06 (Mar 24) to -0.23, marking a decrease of 0.17.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in GKB Ophthalmics Ltd:
- Net Profit Margin: -6.66%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -7.22% (Industry Average ROCE: 6%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -13.53% (Industry Average ROE: 12.7%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -2.06
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.78
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 0)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.27
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -6.66%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Lenses/Optical Care | 16-A, Tivim Industrial Estate, Mapusa Goa 403526 | investor.grievance@gkb.net http://www.gkb.net |
| Management | |
|---|---|
| Name | Position Held |
| Mr. K G Gupta | Chairman & Managing Director |
| Mr. Vikram Gupta | Director |
| Mr. Ninad G Kamat | Director |
| Mr. Purushottam S Mantri | Director |
| Mrs. Sandhya Ajit Kamat | Director |
| Mr. Cedric Lobo | Director |
FAQ
What is the intrinsic value of GKB Ophthalmics Ltd?
GKB Ophthalmics Ltd's intrinsic value (as of 04 November 2025) is 160.11 which is 133.74% higher the current market price of 68.50, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 34.5 Cr. market cap, FY2025-2026 high/low of 112/59.0, reserves of ₹47 Cr, and liabilities of 125 Cr.
What is the Market Cap of GKB Ophthalmics Ltd?
The Market Cap of GKB Ophthalmics Ltd is 34.5 Cr..
What is the current Stock Price of GKB Ophthalmics Ltd as on 04 November 2025?
The current stock price of GKB Ophthalmics Ltd as on 04 November 2025 is 68.5.
What is the High / Low of GKB Ophthalmics Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of GKB Ophthalmics Ltd stocks is 112/59.0.
What is the Stock P/E of GKB Ophthalmics Ltd?
The Stock P/E of GKB Ophthalmics Ltd is .
What is the Book Value of GKB Ophthalmics Ltd?
The Book Value of GKB Ophthalmics Ltd is 103.
What is the Dividend Yield of GKB Ophthalmics Ltd?
The Dividend Yield of GKB Ophthalmics Ltd is 0.00 %.
What is the ROCE of GKB Ophthalmics Ltd?
The ROCE of GKB Ophthalmics Ltd is 6.00 %.
What is the ROE of GKB Ophthalmics Ltd?
The ROE of GKB Ophthalmics Ltd is 12.7 %.
What is the Face Value of GKB Ophthalmics Ltd?
The Face Value of GKB Ophthalmics Ltd is 10.0.